Debt-to-equity of Verrica Pharmaceuticals Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Verrica Pharmaceuticals Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2019 to 31 Dec 2025.
Verrica Pharmaceuticals Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was -697%, a 49% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Verrica Pharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	-697%	-228%	-49%	31 Dec 2025
Q3 2025	-380%	+613%	+62%	30 Sep 2025
Q2 2025	-311%	-801%	-163%	30 Jun 2025
Q1 2025	-339%	-497%	-314%	31 Mar 2025
Q4 2024	-469%	-539%	-771%	31 Dec 2024
Q3 2024	-993%	-1027%	-2968%	30 Sep 2024
Q2 2024	491%	+481%	+5019%	30 Jun 2024
Q1 2024	158%	+122%	+338%	31 Mar 2024
Q4 2023	70%	-11%	-14%	31 Dec 2023
Q3 2023	35%	-87%	-72%	30 Sep 2023
Q2 2023	9.6%	-154%	-94%	30 Jun 2023
Q1 2023	36%	-89%	-71%	31 Mar 2023
Q4 2022	81%	-20%	-20%	31 Dec 2022
Q3 2022	122%	+25%	+26%	30 Sep 2022
Q2 2022	164%	+70%	+74%	30 Jun 2022
Q1 2022	125%	+33%	+36%	31 Mar 2022
Q4 2021	101%	+11%	+12%	31 Dec 2021
Q3 2021	97%	+39%	+68%	30 Sep 2021
Q2 2021	94%	+59%	+169%	30 Jun 2021
Q1 2021	92%	+73%	+394%	31 Mar 2021
Q4 2020	89%	+84%	+1615%	31 Dec 2020
Q3 2020	58%	+53%	+1175%	30 Sep 2020
Q2 2020	35%	+31%	+861%	30 Jun 2020
Q1 2020	19%	+15%	+509%	31 Mar 2020
Q4 2019	5.2%			31 Dec 2019
Q3 2019	4.5%			30 Sep 2019
Q2 2019	3.6%			30 Jun 2019
Q1 2019	3%			31 Mar 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.